A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

Trial Profile

A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Avelumab (Primary) ; PF 4518600 (Primary) ; Utomilumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms JAVELIN Medley
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Nov 2017 Planned End Date changed from 21 Feb 2020 to 1 Feb 2020.
    • 20 Nov 2017 Planned primary completion date changed from 10 Dec 2019 to 1 Dec 2019.
    • 27 Oct 2017 Planned End Date changed from 13 Feb 2020 to 21 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top